NCT05875714已完成2 期
Apremilast for the Treatment of Refractory Erythema Multiforme
Robert Micheletti2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2022年1月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- EM flares on medication
研究概览
简要总结
This study is recruiting patients with chronic, treatment resistant erythema multiforme (EM), which is a disease that can affect the skin and mucous membranes (mucocutaneous). EM often impacts quality of life with pain, anorexia, hospitalization, and related long-term issues. While there are medications used to treat EM, no single therapeutic agent has been consistently effective for long-term management of disease. Apremilast (trade name: Otezla) is approved to treat Bechet's Disease, a different but similar mucocutaneous disease. In this study, eligible patients will receive apremilast for 6 months of treatment so we can evaluate if there is a difference in pain and the number of EM flares compared to prior to treatment with apremilast.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must satisfy the following criteria to be enrolled in the study:
- •Presence of oral, genital, or cutaneous erythema multiforme (EM) diagnosed or confirmed by a dermatologist based on clinical and/or histopathologic data.
- •EM must be recurrent, defined as having =>2 flares in the six months prior to enrollment (or =>4 flares in the year prior to enrollment).
- •EM must be refractory to standard therapy defined as 3-month treatment course with valacyclovir and/or a systemic immunomodulatory therapy such as colchicine, dapsone, azathioprine, mycophenolate mofetil, or methotrexate.
- •Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
- •Willing and able to provide personally signed and dated informed consent form.
- •Stated willingness and ability to comply with all study procedures including adhering to oral apremilast regimen and availability for the duration of the study.
- •Adults aged 18-89 years old.
- •People of childbearing potential (PCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, PCBP who engage in activity by which conception is possible must use one of the approved contraceptive options described below:
- •Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: External or internal condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
- •NOTE: This criterion is satisfied as "not applicable" (N/A) for those who practice abstinence as part of their usual and customary way of life, so long as this is maintained throughout study period plus 28 days post-treatment; are postmenopausal; or are of male sex/assigned male at birth (AMAB).
排除标准
- •The presence of any of the following will exclude a subject from enrollment:
- •Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinological, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
- •Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if they were to participate in the study.
- •Prior history of unmanaged depressive symptoms, suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
- •A score of 4 or higher on Patient Health Questionnaire at screening.
- •Pregnant or breast feeding.
- •Active substance abuse or a history of substance abuse within 6 months prior to Screening.
- •Malignancy or history of malignancy, except for:
- •treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
- •treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.
- •Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
- •Prior treatment with apremilast.
- •Patient unable to comply with study or conform to treatment diary or regular follow up visits.
- •Patients with ocular EM.
- •Concomitant use of immunosuppressive medications for treatment of other diseases.
- •Patients with contraindications to Apremilast according to package insert.
结局指标
主要结局
EM flares on medication
时间窗: 24 weeks
Change in frequency and duration of EM flares at 24-week evaluation.
次要结局
- Pain on medication(24 weeks)
- Pain off medication(36 weeks)
- Flares off medication(36 weeks)
- Prednisone(36 weeks)
研究者
Robert Micheletti
Associate Professor of Dermatology and Medicine
University of Pennsylvania
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Apremilast as anti-pruritic treatment in patients with prurigo nodularisPrurigo nodularisEUCTR2016-003018-29-DKHerlev and Gentofte Hospital20
已完成
3 期
Safety and Efficacy Study of Apremilast to Treat Psoriatic ArthritisPsoriatic ArthritisNCT01925768Amgen219
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet DiseaseBehcet SyndromeNCT00866359Amgen111
已完成
4 期
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.Arthritis, PsoriaticNCT03747939Amgen310
终止
1 期
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast CancerMetastatic Breast CancerNCT00905021Baylor Breast Care Center4